Immunocore to Announce Q2 2024 Financial Results and Host Call on August 8, 2024

Immunocore Holdings plc has announced plans to release its financial results for the second quarter of 2024 before the US markets open on August 8, 2024. Following the release, the company will hold a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss the financial outcomes and provide an update on its business and portfolio developments.

The live audio webcast will be accessible by visiting the ‘Events’ section under ‘Events and Presentations’ in the ‘Investors’ section of Immunocore’s website. A replay of the event will be available for a limited period afterward.

Immunocore is a leading commercial-stage biotechnology firm that is pioneering TCR bispecific immunotherapies, known as ImmTAX (Immune mobilizing monoclonal TCRs Against X disease). These therapies aim to treat various conditions, including cancer, autoimmune diseases, and infectious diseases. The company's proprietary ImmTAX platform is designed to be flexible and off-the-shelf, and it supports a robust pipeline of therapeutic candidates across multiple areas.

One of Immunocore's significant achievements is the development of KIMMTRAK, its most advanced oncology TCR therapeutic. KIMMTRAK has been approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions, including the United States, European Union, Canada, Australia, and the United Kingdom.

The company is actively advancing five clinical-stage programs in oncology and infectious diseases, in addition to advanced preclinical programs targeting autoimmune diseases and several earlier-stage preclinical programs. This extensive pipeline demonstrates Immunocore's commitment to developing innovative treatments that address unmet medical needs across a broad range of diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!